FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FORMELA JEAN FRANCOIS			2. Issuer Name and Intellia Thera		or Tra	ading Symbo	5. 1	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
C/O INTELLIA TH	•	3. Date of Earliest 06/28/2021	Transac	tion (N	/lonth/Day/Ye		Officer (give title Other (specify below) below)							
40 ERIE STREET,		4. If Amendment, D	Date of C	Origina	l Filed (Mont		ndividual or Joint/G	Froup Filing (Che	eck Applicable					
(Street) CAMBRIDGE M	IA 02:	139						Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (S	State) (Zip													
1. Title of Security (In:		- Non-Derivat	ive Securities 2A. Deemed	Acqu	ired,	_			5. Amount of	6. Ownership	hip 7. Nature of			
	o,	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)			
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		· ,			
Common Stock ⁽¹⁾		06/28/2021		S		26,019	D	\$127.02(2)	537,357	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		55,525	D	\$127.79 ⁽³⁾	481,832	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		56,280	D	\$128.77(4)	425,552	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		48,724	D	\$129.88(5)	376,828	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		66,468	D	\$130.79 ⁽⁶⁾	310,360	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		53,823	D	\$131.82 ⁽⁷⁾	256,537	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		56,188	D	\$132.77(8)	200,349	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		36,519	D	\$133.77(9)	163,830	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		30,831	D	\$134.86(10)	132,999	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		21,893	D	\$135.83(11)	111,106	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		3,033	D	\$137.01(12)	108,073	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		5,400	D	\$138.05(13)	102,673	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		4,201	D	\$138.58(14)	98,472	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		52,320	D	\$139.96(15)	46,152	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		8,027	D	\$140.8(16)	38,125	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		8,420	D	\$141.66 ⁽¹⁷⁾	29,705	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		13,556	D	\$142.88(18)	16,149	I	See Footnote ⁽²⁰⁾			
Common Stock ⁽¹⁾		06/28/2021		S		6,149	D	\$143.45(19)	10,000	I	See Footnote ⁽²⁰⁾			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

- 1. Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$126.32 \$127.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$127.32 \$128.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$128.32 \$129.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$129.32 \$130.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4.
- 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$130.32 \$131.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$131.32 \$132.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$132.32 \$133.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4.
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$133.32 \$134.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (9) of this Form 4.
- 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$134.32 \$135.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (10) of this Form 4.
- 11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$135.32 \$136.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (11) of this Form 4.
- 12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$136.32 \$137.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (12) of this Form 4.
- 13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$137.32 \$138.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (13) of this Form 4.
- 14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$138.32 \$139.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (14) of this Form 4.
- 15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$139.32 \$140.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (15) of this Form 4.
- 16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$140.32 \$141.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (16) of this Form 4.
- 17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$141.32 \$142.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (17) of this Form 4.
- 18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$142.32 \$143.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (18) of this Form 4.
- 19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from \$143.32 \$144.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (19) of this Form 4.
- 20. Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney (incorporated by reference to Exhibit 24, Power of Attorney, filed on Form 4 with the SEC on March 13, 2017 by the reporting person)

By: /s/ Frank Castellucci, Attorney-In-Fact 06/28/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of <u>Ommer Chohan</u> and <u>Frank Castellucci</u>, or either of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Intellia Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 4, 2016.

/s/ Jean-Francois Formela						
Signature						
Jean-Francois Formela						
Print Name						